Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Estradiol + Norethindrone + Relugolix |
Synonyms | |
Therapy Description |
Relugolix (TAK-385) is a gonadotropin-releasing hormone antagonist, which binds to the gonadotropin-releasing hormone receptor, thereby preventing the secretion and release of luteinizing hormone and follicle stimulating hormone and possibly resulting in anti-tumor activity (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Estradiol | Alora | 17B Estradiol | ||
Norethindrone | Anhydrohydroxynorprogesterone | Norethisterone | ||
Relugolix | TAK-385|Relumina | Relugolix (TAK-385) is a gonadotropin-releasing hormone antagonist, which binds to the gonadotropin-releasing hormone receptor, thereby preventing the secretion and release of luteinizing hormone and follicle stimulating hormone and possibly resulting in anti-tumor activity (PMID: 32469183). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|